CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Stock Price, Quote, News and Overview
NASDAQ:CYCCP - Nasdaq - US23254L2079 - Currency: USD
CYCCP Quote, Performance and Key Statistics
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP
NASDAQ:CYCCP (2/21/2025, 8:11:33 PM)
7.39
-0.55 (-6.93%)
The current stock price of CYCCP is 7.39 USD. In the past month the price decreased by -10.96%. In the past year, price decreased by -53.52%.
CYCCP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CYCCP
Company Profile
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Berkeley Heights, New Jersey. The firm is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The firm's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
Company Info
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP
200 Connell Dr Ste 1500
Berkeley Heights NEW JERSEY 07922 US
CEO: Spiro Rombotis
Employees: 12
Company Website: https://cyclacel.com/
Investor Relations: http://investor.cyclacel.com/
Phone: 19085177330
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP / CYCCP FAQ
What is the stock price of CYCLACEL PHARMACEUTICALS - CYCC 6 PERP today?
The current stock price of CYCCP is 7.39 USD. The price decreased by -6.93% in the last trading session.
What is the ticker symbol for CYCLACEL PHARMACEUTICALS - CYCC 6 PERP stock?
The exchange symbol of CYCLACEL PHARMACEUTICALS - CYCC 6 PERP is CYCCP and it is listed on the Nasdaq exchange.
On which exchange is CYCCP stock listed?
CYCCP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CYCLACEL PHARMACEUTICALS - CYCC 6 PERP stock?
6 analysts have analysed CYCCP and the average price target is 18.95 USD. This implies a price increase of 156.39% is expected in the next year compared to the current price of 7.39. Check the CYCLACEL PHARMACEUTICALS - CYCC 6 PERP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CYCLACEL PHARMACEUTICALS - CYCC 6 PERP worth?
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) has a market capitalization of 83.21M USD. This makes CYCCP a Micro Cap stock.
How many employees does CYCLACEL PHARMACEUTICALS - CYCC 6 PERP have?
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) currently has 12 employees.
What are the support and resistance levels for CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) stock?
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) has a support level at 7.38 and a resistance level at 7.95. Check the full technical report for a detailed analysis of CYCCP support and resistance levels.
Is CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) expected to grow?
The Revenue of CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) is expected to decline by -86.38% in the next year. Check the estimates tab for more information on the CYCCP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CYCCP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CYCCP, evaluating the profitability, health, valuation and growth aspects
- CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Sales and EPS estimates to see what analysts future expectations are.
- CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Insider and Institutional Ownership to learn about the owners and their transactions.
- CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Stock Chart to make your own analysis
- CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Latest news and press-releases to stay up to date.
Does CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) stock pay dividends?
CYCCP does not pay a dividend.
When does CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) report earnings?
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) will report earnings on 2025-03-17, after the market close.
What is the Price/Earnings (PE) ratio of CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP)?
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.4).
CYCCP Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CYCCP. When comparing the yearly performance of all stocks, CYCCP is a bad performer in the overall market: 87.74% of all stocks are doing better.
CYCCP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CYCCP. Both the profitability and financial health of CYCCP have multiple concerns.
CYCCP Financial Highlights
Over the last trailing twelve months CYCCP reported a non-GAAP Earnings per Share(EPS) of -9.4. The EPS increased by 68.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -250.53% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CYCCP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to CYCCP. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 92.7% and a revenue growth -86.38% for CYCCP